Evidence map›Paper›PMID 35730949›Full record

ArticleJournal of clinical microbiology2022

Limitations of Molecular and Antigen Test Performance for SARS-CoV-2 in Symptomatic and Asymptomatic COVID-19 Contacts.

Matthew L Robinson, Agha Mirza, Nicholas Gallagher, Alec Boudreau, Lydia Garcia Jacinto, Tong Yu, Julie Norton, Chun Huai Luo, Abigail Conte, Ruifeng Zhou and 7 more

Abstract read
In one paragraph

Article in Journal of clinical microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Matthew L RobinsonDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicinegrid.471401.7, Baltimore, Maryland, USA.ORCID 0000-0003-0376-8560
Agha MirzaDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicinegrid.471401.7, Baltimore, Maryland, USA.
Nicholas GallagherDepartment of Pathology, Johns Hopkins University School of Medicinegrid.471401.7, Baltimore, Maryland, USA.
Alec BoudreauDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicinegrid.471401.7, Baltimore, Maryland, USA.
Lydia Garcia JacintoDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicinegrid.471401.7, Baltimore, Maryland, USA.
Tong YuDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicinegrid.471401.7, Baltimore, Maryland, USA.
Julie NortonDepartment of Pathology, Johns Hopkins University School of Medicinegrid.471401.7, Baltimore, Maryland, USA.
Chun Huai LuoDepartment of Pathology, Johns Hopkins University School of Medicinegrid.471401.7, Baltimore, Maryland, USA.
Abigail ConteDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Ruifeng ZhouDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Kim KafkaClinical Research Unit, Johns Hopkins Institute for Clinical and Translational Research, Baltimore, Maryland, USA.
Justin HardickDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicinegrid.471401.7, Baltimore, Maryland, USA.
David D McManusDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts T.H. Chan Medical School, Worcester, Massachusetts, USA.
Laura L GibsonDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts T.H. Chan Medical School, Worcester, Massachusetts, USA.
Andrew PekoszDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0003-3248-1761
Heba H MostafaDepartment of Pathology, Johns Hopkins University School of Medicinegrid.471401.7, Baltimore, Maryland, USA.ORCID 0000-0002-0274-8966
Yukari C ManabeDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicinegrid.471401.7, Baltimore, Maryland, USA.

Funding

The Center for Advancing Point of Care in Heart, Lung, Blood and Sleep DiseasesU54HL143541 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Nathaniel Scott Hafer · 2018 to 2026
$141.0M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
TrainingU54EB007958 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI Yukari C Manabe, Susan Anne Tuddenham · 2007 to 2026
$34.6M
SUPPORT-AF IVR01HL155343 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KAPOOR, ALOK · 2021 to 2025
$3.4M
Smartwatch Monitoring for Atrial Fibrillation After StrokeR01HL137734 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CHON, KI H, MCMANUS, DAVID D. · 2018 to 2021
$3.1M
FHS-NEXT - Framingham Novel EXam using TechnologyR01HL141434 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BENJAMIN, EMELIA J., MCMANUS, DAVID D. · 2019 to 2022
$2.5M
A phase I trial of AdKCNH2-G628S gene therapy for post-op atrial fibrillationR61HL158541 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI DONAHUE, J KEVIN, MCMANUS, DAVID D. · 2021 to 2021
$419k
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI272201400007CNHLBI NIH HHS R01 HL137734NHLBI NIH HHS R01 HL141434NHLBI NIH HHS R01 HL155343NHLBI NIH HHS R61 HL158541NHLBI NIH HHS U54 HL143541NIAID NIH HHS UM1 AI068613NIBIB NIH HHS U54 EB007958
6 · The paper itself

Abstract

COVID-19 has brought unprecedented attention to the crucial role of diagnostics in pandemic control. We compared severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test performance by sample type and modality in close contacts of SARS-CoV-2 cases. Close contacts of SARS-CoV-2-positive individuals were enrolled after informed consent. Clinician-collected nasopharyngeal (NP) swabs in viral transport media (VTM) were tested with a routine clinical reference nucleic acid test (NAT) and PerkinElmer real-time reverse transcription-PCR (RT-PCR) assay; positive samples were tested for infectivity using a VeroE6TMPRSS2 cell culture model. Self-collected passive drool was also tested using the PerkinElmer RT-PCR assay. For the first 4 months of study, midturbinate swabs were tested using the BD Veritor rapid antigen test. Between 17 November 2020 and 1 October 2021, 235 close contacts of SARS-CoV-2 cases were recruited, including 95 with symptoms (82% symptomatic for ≤5 days) and 140 asymptomatic individuals. Reference NATs were positive for 53 (22.6%) participants; 24/50 (48%) were culture positive. PerkinElmer testing of NP and saliva samples identified an additional 28 (11.9%) SARS-CoV-2 cases who tested negative by reference NAT. Antigen tests performed for 99 close contacts showed 83% positive percent agreement (PPA) with reference NAT among early symptomatic persons, but 18% PPA in others; antigen tests in 8 of 11 (72.7%) culture-positive participants were positive. Contacts of SARS-CoV-2 cases may be falsely negative early after contact, but more sensitive platforms may identify these cases. Repeat or serial SARS-CoV-2 testing with both antigen and molecular assays may be warranted for individuals with high pretest probability for infection.

Indexed as

COVID-19SARS-CoV-2COVID-19 TestingHumansPandemicsSensitivity and SpecificityCOVID-19rapid diagnosticsSARS-CoV-2test performance

Identifiers

PMID35730949
PMCPMC9297839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.